Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

With a market cap of around $730 billion, Eli Lilly (NYSE: LLY) is one of the largest pharmaceutical companies on planet ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

or he could be attempting to push the company into accepting the price by creating public demand for it. Following the statement, both Novo Nordisk and Eli Lilly saw their stock prices dip. While the ...

Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

According to Benzinga Pro, Eli Lilly and Co's peer group average for short interest as a percentage of float is 3.60%, which ...